China’s CDE Releases 105th Batch of Reference Preparations for Generic Drug Evaluation, Adds 8 New Drugs
China’s Center for Drug Evaluation (CDE) has published the 105th batch of reference preparations for...
Eli Lilly Secures FDA Approval for Foundayo (Orforglipron) in Obesity Treatment, Shipments Begin April 6
Eli Lilly and Company (NYSE: LLY) announced it has received marketing approval from the US...
Eisai Expands Dayvigo Access in China with 14-Tablet Specification Across E-Commerce and Digital Health Platforms
Eisai Co., Ltd. (TYO: 4523) announced the commercial launch of a 14-tablet specification of its...
China’s NMPA Unveils Ambitious “AI + Drug Regulation” Roadmap Through 2035
China’s National Medical Products Administration (NMPA) today released its comprehensive “Implementation Opinions on ‘AI +...
Shanghai BDgene Secures Hundreds of Millions in Financing to Advance Dual Gene Therapy Platforms
Shanghai BDgene Technology Co., Ltd. announced the successful closing of a financing round securing hundreds...
Fosun Pharma Secures NMPA Clearance for Two Novel Therapeutics: PD-1/IL-2 Fusion FXB0871 and Recombinant Hyaluronidase HLXTE-HAase02
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced it has received clearance...
Rui Therapeutics Secures NMPA Approval for KN5501 CAR-NK Therapy in Autoimmune Diseases
Rui Therapeutics, a China-based cell therapy developer, announced it has received approval from the National...
Changchun High & New Receives NMPA Approval for GenSci161 Clinical Study in Endometriosis and Hidradenitis Suppurativa
Changchun High & New Technology Industries (Group) Inc. (SHE: 000661) announced it has received approval...
Sirius Therapeutics Files Hong Kong IPO Application with siRNA Pipeline Targeting Coagulation and Cardiometabolic Diseases
Sirius Therapeutics, a clinical-stage biotechnology company founded in 2021, announced it has submitted its listing...
Alphamab Oncology’s Anbenitamab Meets Primary Endpoint in Phase III HER2+ Breast Cancer Neoadjuvant Study
Alphamab Oncology (HKG: 9966) announced that the Phase III KN026-004 clinical study evaluating anbenitamab in...
Sanofi Secures EU Conditional Approval for Rezurock in Chronic Graft-Versus-Host Disease
Sanofi (NASDAQ: SNY) announced that the European Commission (EC) has granted conditional marketing authorization for...
Gilead and Galapagos Forge $2.175 Billion T-Cell Engager Collaboration for Autoimmune Diseases Following Ouro Medicines Acquisition
Gilead Sciences Inc. (NASDAQ: GILD) and Galapagos NV (NASDAQ: GLPG) announced a comprehensive collaboration to...
Merck & Co. Partners with Infinimmune for $838 Million Antibody Discovery Collaboration Using Human-First Platform
Merck & Co., Inc. (MSD; NYSE: MRK) announced a strategic collaboration with fellow US biotech...
Biogen Secures FDA Approval for High-Dose Spinraza Regimen in Spinal Muscular Atrophy
Biogen Inc. (NASDAQ: BIIB) announced that the U.S. Food and Drug Administration (FDA) has approved...
AstraZeneca Reports Positive Phase III Results for Efzimfotase Alfa in Hypophosphatasia Across Pediatric and Adult Populations
AstraZeneca (NYSE: AZN) announced positive results from its comprehensive Phase III clinical program for efzimfotase...
Otsuka Pharmaceutical to Acquire Transcend Therapeutics for Up to $1.225 Billion to Expand Neuropsychiatric Pipeline
Otsuka Pharmaceutical Co., Ltd. (OTCMKTS: OTSKY) announced plans to fully acquire US-based Transcend Therapeutics, Inc....
Novo Nordisk Launches Wegovy Subscription Program to Improve Obesity Treatment Access and Affordability
Novo Nordisk (NYSE: NVO) announced a new multi-month subscription program for Wegovy (semaglutide) that offers...
Gan & Lee Pharmaceuticals’ Once-Weekly Insulin GZR4 Demonstrates Superior HbA1c Reduction in Phase III Trials
Gan & Lee Pharmaceuticals (SHA: 603087) announced that two pivotal Phase III clinical studies, SUPER-1...
Abbisko Therapeutics Secures EMA Orphan Drug Designation for Irpagratinib in Hepatocellular Carcinoma
Abbisko Therapeutics Co., Ltd. (HKG: 2256) announced that the European Medicines Agency (EMA) has granted...
MicroPort Scientific Returns to Profitability as Global Access Platform Drives 78.8% Revenue Surge
MicroPort Scientific Corp. (HKG: 0853) announced its 2025 full-year financial results, reporting a return to...